These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 30578392)

  • 1. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
    Lu J; Zhong H; Chu T; Zhang X; Li R; Sun J; Zhong R; Yang Y; Alam MS; Lou Y; Xu J; Zhang Y; Wu J; Li X; Zhao X; Li K; Lu L; Han B
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
    Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
    Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.
    Lu J; Xu W; Qian J; Wang S; Zhang B; Zhang L; Qiao R; Hu M; Zhao Y; Zhao X; Han B
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):38. PubMed ID: 30871526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
    Wu M; Jin MM; Cao XH; Zhao L; Li YH
    Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
    Wang S; Lou N; Luo R; Hao X; Liu Y; Wang L; Shi Y; Han X
    J Transl Med; 2022 May; 20(1):248. PubMed ID: 35642002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
    Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
    Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of
    Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
    Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
    [No Abstract]   [Full Text] [Related]  

  • 11. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
    Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
    Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
    Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
    JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
    Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
    J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells.
    Zhang LL; Lu J; Liu RQ; Hu MJ; Zhao YM; Tan S; Wang SY; Zhang B; Nie W; Dong Y; Zhong H; Zhang W; Zhao XD; Han BH
    Acta Pharmacol Sin; 2020 Oct; 41(10):1357-1365. PubMed ID: 32415222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib].
    Huang L; Qin Y; Zhao F; Zhou S; Shi Y
    Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):739-742. PubMed ID: 34628779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yu G; Shen Y; Xu X; Zhong F
    PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
    Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
    Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.